



#19

RECEIVED

APR 24 2003

TECH CENTER 1600/2900

RECEIVED

APR 23 2003

GROUP 1700




Figure 1A

Figure 1B





Figure 1C



IgG fractions

50 mg and 10 mg groups dosed 1qwk;

placebos dosed 1, 2 or 4 per month

visit 2 = pre-drug baseline


visit 11 = pre-dose sample


★  $p < 0.05$

★★  $p < 0.01$


Figure 3A

Figure 3B







**Figure 4A**





**Figure 4B**





**Figure 4C**




**Figure 4D**








## High Affinity




## Low Affinity



■ Baseline  
 ▨ 4 months


Figure 8






- \* analysis includes 69 of 114 patients treated with LPJ 394
- \* analysis includes 14 of 19 lupus flares from drug treated group


Figure 11A



**Figure 11B**




**Figure 11C**



\* data represents 15 of 19 LJP flares and 14 of 23 placebo flares

Figure 12




\* analysis includes 36 of 115 patients treated with placebo graph identifies 14 of 23 lupus flares from placebo treated group

Figure 13



Placebo n = 95  
 Active n = 91

Figure 16




<sup>1</sup> HDCC = First incidence of high dose corticosteroids +/- cyclophosphamide

<sup>2</sup> Major lupus flare: hospitalization (due to SLE), first occurrence of high dose prednisone, any cyclophosphamide, death due to SLE



Placebo n = 106  
LJP 394 n = 105

Figure 17



No. of patients 23 19

Time to Event p=.522

Incidence p=.606

<sup>1</sup> HDCC = First incidence of high dose corticosteroids +/- cyclophosphamide

<sup>2</sup> Major lupus flare: hospitalization (due to SLE), first occurrence of high dose prednisone, any cyclophosphamide, death due to SLE